ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
34.85
-0.14%
US Tech 100
19,245.20
0.42%
S&P 500
5,475.09
0.27%
US Dollar vs CAD
1.3743
0.03%
Bitcoin
62,855.02
0.01%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Lexeo Therapeutics Inc (LXEO)

  7. Lexeo Therapeutics Inc (LXEO) News

LXEO

Lexeo Therapeutics (LXEO)

Lexeo Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:LXEO
DateTimeSourceHeadlineSymbolCompany
06/14/20248:04AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXEOLexeo Therapeutics Inc
06/12/20244:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXEOLexeo Therapeutics Inc
05/22/20244:03PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:LXEOLexeo Therapeutics Inc
05/14/20243:04PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXEOLexeo Therapeutics Inc
05/13/20244:14PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LXEOLexeo Therapeutics Inc
05/09/20246:09AMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:LXEOLexeo Therapeutics Inc
05/09/20246:07AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LXEOLexeo Therapeutics Inc
05/09/20246:02AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LXEOLexeo Therapeutics Inc
05/09/20246:00AMGlobeNewswire Inc.Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational HighlightsNASDAQ:LXEOLexeo Therapeutics Inc
05/07/20246:30AMGlobeNewswire Inc.Lexeo Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:LXEOLexeo Therapeutics Inc
04/22/20246:30AMGlobeNewswire Inc.Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia CardiomyopathyNASDAQ:LXEOLexeo Therapeutics Inc
04/16/20246:30AMGlobeNewswire Inc.Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia CardiomyopathyNASDAQ:LXEOLexeo Therapeutics Inc
03/13/20243:22PMGlobeNewswire Inc.Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity FinancingNASDAQ:LXEOLexeo Therapeutics Inc
03/11/20243:11PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LXEOLexeo Therapeutics Inc
03/11/20243:09PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:LXEOLexeo Therapeutics Inc
03/11/20248:29AMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:LXEOLexeo Therapeutics Inc
03/11/20246:42AMGlobeNewswire Inc.Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational HighlightsNASDAQ:LXEOLexeo Therapeutics Inc
03/11/20246:30AMGlobeNewswire Inc.Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity FinancingNASDAQ:LXEOLexeo Therapeutics Inc
02/06/20244:58PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:LXEOLexeo Therapeutics Inc
02/06/20244:56PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXEOLexeo Therapeutics Inc
02/05/20246:03AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LXEOLexeo Therapeutics Inc
02/05/20246:00AMGlobeNewswire Inc.Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive AppointmentsNASDAQ:LXEOLexeo Therapeutics Inc
01/03/20246:00AMGlobeNewswire Inc.Lexeo Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:LXEOLexeo Therapeutics Inc
12/18/20236:00AMGlobeNewswire Inc.Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM)NASDAQ:LXEOLexeo Therapeutics Inc
12/11/20236:00AMGlobeNewswire Inc.Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational HighlightsNASDAQ:LXEOLexeo Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:LXEO

Your Recent History

TG
P21
First Atlantic Nickel
LSE
GILE
Inf Gv Bd E Hd
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved